Some patients with common kidney disease can skip standard treatments

September 6, 2012 in Diseases, Conditions, Syndromes

For patients with a common kidney disease who have normal kidney function and only minor urinary abnormalities at the time of diagnosis, the long-term prognosis is excellent and no special treatments are needed, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings contrast with earlier, smaller studies and suggest that patients can avoid taking potentially toxic immunosuppressive medications often used to treat the disease.

IgA nephropathy occurs when antibodies build up in the kidneys, which can cause the kidneys to leak blood and proteins into the urine and in some cases can lead to . But some patients with IgA nephropathy have normal kidney function and only minor urinary abnormalities at the time of diagnosis. The long-term prognosis of these patients is unclear.

To investigate, Eduardo Gutiérrez, MD, Manuel Praga, MD, PhD (Hospital Universitario 12 de Octubre, in Madrid), and their colleagues studied 141 with biopsy-proven IgA nephropathy who had normal kidney function, little or no urinary protein leakage, or , and who were not taking immunosuppressive medications for their disease.

Among the major findings:

  • After 10, 15, and 20 years, 96.7%, 91.9%, and 91.9% of patients maintained blood creatinine levels under a 50% increase from the start, respectively. (Rising creatinine levels indicate declining kidney function.) No patients developed kidney failure.
  • Clinical remission occurred in 53 (37.5%) patients after an average of four years.
  • 41 (29.1%) patients had no proteinuria.
  • At the start of the study, 23 (16.3%) patients had compared with 30 (21.3%) patients at the end of follow-up.
  • 59 (41.8%) patients were treated with medications that lower high blood pressure and proteinuria.
"We demonstrate that the long-term prognosis of this type of patient is excellent and that no special treatments other than those needed to lower blood pressure or treat increasing proteinuria are indicated," said Dr. Gutiérrez. "Our reassuring data are important because some previous studies had suggested that IgA nephropathy is a progressive disease even in this type of patient with benign presentation," he added.

More information: The article, entitled "Long-Term Outcomes of IgA Nephropathy Presenting with Minimal or No Proteinuria will appear online on September 6, 2012, doi: 10.1681/ASN.2012010063

Journal reference: Journal of the American Society of Nephrology search and more info website

Provided by American Society of Nephrology search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Little evidence for prediction rules for low back pain

(HealthDay)—Few randomized clinical trials have been done to assess clinical prediction rules for patients with lower back pain, and the trials that have been done are of low quality and do not provide ...

Diseases, Conditions, Syndromes created 12 hours ago | popularity not rated yet | comments 0 | with audio podcast

New malaria test kit gives a boost to elimination efforts worldwide

A new, highly sensitive blood test that quickly detects even the lowest levels of malaria parasites in the body could make a dramatic difference in efforts to tackle the disease in the UK and across the world, according to ...

Diseases, Conditions, Syndromes created 17 hours ago | popularity not rated yet | comments 0

WHO says single yellow fever shot is enough

(AP)—The World Health Organization says a yellow fever booster vaccination given 10 years after the initial shot isn't necessary.

Diseases, Conditions, Syndromes created 17 hours ago | popularity not rated yet | comments 0

23 dead in initiation rites in South Africa

(AP)—Twenty-three youths have died in the past nine days at initiation ceremonies that include circumcisions and survival tests, South African police said Friday.

Diseases, Conditions, Syndromes created 18 hours ago | popularity 5 / 5 (1) | comments 2

Expert questions US public health agency advice on influenza vaccines

The United States government public health agency, the CDC, pledges "To base all public health decisions on the highest quality scientific data, openly and objectively derived." But Peter Doshi, a postdoctoral fellow at Johns ...

Diseases, Conditions, Syndromes created May 16, 2013 | popularity not rated yet | comments 0


AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests

Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...

Temporal processing in the olfactory system

The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...

Melon focus headband turns to Kickstarter for rollout plans

(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...

Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...